Surrozen, Inc (SRZN): Price and Financial Metrics
GET POWR RATINGS... FREE!
SRZN Stock Price Chart Interactive Chart >
SRZN Price/Volume Stats
| Current price | $2.77 | 52-week high | $14.00 |
| Prev. close | $2.55 | 52-week low | $1.98 |
| Day low | $2.48 | Volume | 2,600 |
| Day high | $2.77 | Avg. volume | 70,479 |
| 50-day MA | $2.85 | Dividend yield | N/A |
| 200-day MA | $5.55 | Market Cap | 97.30M |
Surrozen, Inc (SRZN) Company Bio
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are highly expressed in intestinal crypts. The company was founded in 2016 and is headquartered in South San Francisco, California.
Latest SRZN News From Around the Web
Below are the latest news stories about Surrozen Inc that investors may wish to consider to help them evaluate SRZN as an investment opportunity.
Heartland Express, Inc. Reports Fourth Quarter and Annual Financial Results which includes All-Time Record High Annual Earnings Per ShareNORTH LIBERTY, Iowa, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Heartland Express, Inc. (Nasdaq: HTLD) announced today financial results for the quarter and year ended December 31, 2021. Three months ended December 31, 2021: Net Income of $20.3 million and Basic Earnings per Share of $0.26, Operating Revenue of $148.1 million,Operating Income of $26.5 million, an 11.5% increase over 2020,Operating Ratio of 82.1% and 79.2% Non-GAAP Adjusted Operating Ratio(1),Cash balance of $157.7 million and a Debt-Free |
Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline-Initiation of Phase 1 clinical trials of SZN-1326 and SZN-043 expected in third quarter 2022 -Acceleration of preclinical programs includes nomination of lead candidate SZN-413 for retinopathies and compelling preclinical data highlighting the potential for lacrimal gland and lung programs SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulate the Wnt pathway |
Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare ConferenceSurrozen to provide a business update including discussion of pipeline advancementsSOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, will present virtually on January 13, 2022 at 9 a.m. ET, at the 40th J.P. Morgan Healthcare Conference. A live audio webcast of the presentation will be accessible through |
Surrozen Reports Third Quarter 2021 Financial ResultsProduct Candidates SZN-1326 and SZN-043 Advance Toward Initiation of Clinical Studies in 2022 Expanding and Advancing Discovery Stage Pipeline in Multiple Disease Settings SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today reported financial results for the third quarter ended September 30, 2021 and |
Surrozen to Present at The Piper Sandler 33rd Annual Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc., (NASDAQ: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Craig Parker, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference at 10:00 a.m. ET on Monday, November 22. Interested parties may access the live webcast via the Investors section of the Surrozen website |
SRZN Price Returns
| 1-mo | 0.73% |
| 3-mo | -3.82% |
| 6-mo | -69.46% |
| 1-year | -71.94% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -56.99% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...